about
Does beta blockade postinjury prevent bone marrow suppression?Structured communication: teaching delivery of difficult news with simulated resuscitations in an emergency medicine clerkship.Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.β-blockade protection of bone marrow following trauma: the role of G-CSF.Activation of KRAS mediates resistance to targeted therapy in MET ex on 14 mutant non-small cell lung cancerAssociation Among Hypoxemia, Patent Foramen Ovale, and Mediastinal Germ Cell Tumor: A Case ReportEvolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiationMAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusionsTumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung CancersEntrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumorsHER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung CancersLiquid biopsy guided precision therapy for lung cancersTumor-Agnostic Drug DevelopmentHigh Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenTumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung CancerFrequency and outcomes of brain metastases in patients with HER2-mutant lung cancersRadiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
P50
Q35010177-5478284E-E0E4-4578-B4CE-FDE64AA26867Q35235085-A65DC42C-0461-4E8A-85B6-3F53A467D7D3Q37723666-E3EE03AB-C20B-4B3E-BBCF-42D1F62A33BEQ42871038-D3C64CE5-5E48-45AC-87C5-4BB3E00650D5Q57796537-80AD48A7-7E49-4B90-A765-564531273DAFQ85706843-64A9BAFF-6FD8-4BF0-9000-21DDEB10CFB2Q89293671-3E92C82B-A3C4-47D2-8402-2685B4763686Q89982405-FC65B537-8E0F-46C0-A98F-140398C97813Q90473934-92E0DD5B-61A4-40B5-9E99-4134A700A120Q90528991-0C6EAF1F-549D-479E-A571-9CF85C02CC99Q90659981-5A5CA3F6-A428-43F7-B55B-96D6CFDCA58EQ90991545-93D0E5E7-FB0F-43A6-91BD-F24D0943A0D8Q91546426-11571D40-266C-48B6-B719-B1A780EA9021Q91555914-1FBC5181-078A-4AF4-ABF3-2B35C668F3CDQ92479898-2CD1D258-FD2C-4D42-BA80-23939F678406Q93009474-E8E2A03F-672E-4D6B-AA09-2594CCF758B0Q94558765-590A8E5E-2AAB-487E-849C-CF9258CBD516
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Michael D Offin
@en
Michael D Offin
@nl
type
label
Michael D Offin
@en
Michael D Offin
@nl
prefLabel
Michael D Offin
@en
Michael D Offin
@nl
P31
P496
0000-0002-7959-3018